AZN vs NVO Comparison: AI Score, Valuation, Performance and Upside
Compare AstraZeneca and Novo Nordisk ADRs by oncology breadth vs GLP-1 obesity drug dominance, pipeline reinvestment, revenue growth trajectory, and which European pharmaceutical giant offers better long-term earnings power.
Use this AstraZeneca vs Novo Nordisk comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
AZN holds the edge across 3 of 5 key metrics in this comparison. AZN has delivered stronger 1-year price return (+16.87% vs -27.71%), though NVO has the better forward P/E setup (2.28x vs 19.29x for AZN). Analyst consensus implies meaningfully more upside for AZN (+26.37%) than for NVO (-3.06%).
| Metric | AZN | NVO |
|---|---|---|
| AI score | 52.0 | 39.0 |
| AI rank | #388 | #1252 |
| Latest close | $169.26 | $48.77 |
| 1M return | -7.52% | +2.87% |
| 6M return | -6.74% | -18.76% |
| 1Y return | +16.87% | -27.71% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | AZN | NVO |
|---|---|---|
| 1Y ago | $11.89K (+18.9%) started 2025-07-24 | $7.57K (-24.3%) started 2025-07-24 |
| 5Y ago | $18.49K (+84.9%) started 2021-07-26 | $13.59K (+35.9%) started 2021-07-26 |
| 10Y ago | $50.19K (+401.9%) started 2016-07-25 | $28.67K (+186.7%) started 2016-07-25 |
Hypothetical — past performance does not guarantee future results.
| Metric | AZN | NVO |
|---|---|---|
| Market cap | $262.5B | $215.7B |
| Trailing P/E | 25.45 | 11.67 |
| Forward P/E | 19.29 | 2.28 |
| Price/Sales | 4.46 | 0.66 |
| EV/Revenue | 4.75 | 1.03 |
| Analyst target | $213.89 | $47.28 |
| Target upside | +26.37% | -3.06% |
| Metric | AZN | NVO |
|---|---|---|
| Revenue growth | 12.50% | 24.00% |
| Earnings growth | 5.30% | 67.10% |
| EPS growth | +5.30% | +67.10% |
| FCF margin | +10.85% | -3.67% |
| Operating margin | N/A | N/A |
| Profit margin | 17.19% | 37.21% |
| ROIC proxy | 23.48% | 71.40% |
| Return on equity | 23.48% | 71.40% |
| Dividend yield | 1.88% | 3.74% |
| Beta | 0.23 | 0.36 |
| Debt/equity | 71.81 | 72.09 |
| Current ratio | 0.91 | 0.79 |
| Quick ratio | 0.70 | 0.54 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | AZN | NVO |
|---|---|---|---|
| 1Y | Growth | +16.87% | -27.71% |
| CAGR | +16.88% | -27.73% | |
| Sharpe ratio | 0.54 | -0.45 | |
| Max drawdown | 21.15% | 49.17% | |
| Max daily drop | 5.70% | 21.83% | |
| Max wkly drop | 14.82% | 33.45% | |
| 5Y | Growth | +65.56% | +21.64% |
| CAGR | +10.62% | +4.00% | |
| Sharpe ratio | 0.35 | 0.18 | |
| Max drawdown | 27.87% | 74.70% | |
| Max daily drop | 8.83% | 21.83% | |
| Max wkly drop | 14.82% | 33.45% | |
| 10Y | Growth | +261.68% | +122.08% |
| CAGR | +13.72% | +8.31% | |
| Sharpe ratio | 0.46 | 0.27 | |
| Max drawdown | 27.87% | 74.70% | |
| Max daily drop | 14.91% | 21.83% | |
| Max wkly drop | 16.45% | 33.45% |
| Category | AZN | NVO |
|---|---|---|
| Company | AZN | NVO |
| Sector | N/A | N/A |
| Industry | N/A | N/A |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.